secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2025-08-01T23:59:59+00:00
Accession:  0001682852-25-000041
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna Q2 net loss $0.8B, rev $142M (-41% YoY); cuts 2025 revenue guidance high end by $300M
--------------------------------------------------------------------------------

- Q2 revenue $142M (-41% YoY); GAAP net loss $0.8B ($2.13 EPS loss).
- 2025 revenue guidance narrowed to $1.5-$2.2B (high end cut $300M due to UK delivery timing shift to 2026).
- GAAP operating expenses expected $5.9-$6.1B, improved ~$400M; year-end cash ~$6B reiterated.
- Announced three FDA approvals (mNEXSPIKE for high-risk adults, Spikevax for children, mRESVIA for 18-59) and positive Phase 3 flu vaccine efficacy data.
- Restructuring: global workforce reduction of ~10%, targeting headcount under 5,000 by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285225000041/0001682852-25-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285225000041/mrna-20250801.htm
  HTML page:      https://secwatch.observer/filing/0001682852-25-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer